Drugs / rezivertinib
Trials 6 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT04135820 | Dec 2019 → Mar 2020 | non-small cell lung carcinoma | Beta Pharma, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT04135833 | Dec 2019 → Jul 2020 | non-small cell lung carcinoma | Beta Pharma, Inc. | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03386955 | Aug 2017 → Dec 2021 | non-small cell lung carcinoma | Beta Pharma Shanghai | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT03812809 | Jul 2019 → Jan 2022 | non-small cell lung carcinoma | Beta Pharma Shanghai | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT06955325 | May 2025 → Dec 2030 expected | non-small cell lung carcinoma | The First Affiliated Hospital of Guangzhou Medical University | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT03866499 | Apr 2021 → Nov 2023 overdue | non-small cell lung carcinoma | Beta Pharma Shanghai | Active not recruiting | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | rezivertinib | “This study aimed to compare the efficacy and safety of rezivertinib (BPI-7711) and gefitinib as first-line therapies in patients with EGFR-mutated locally advanced or...” PMID 39914443 ↗ Feb 20252“Rezivertinib (BPI-7711) is a novel third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI).” PMID 37163774 ↗ Apr 2023 |
| Known as | BPI-7711 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03812809 ↗ |
| Action | Inhibit | “tyrosine kinase inhibitor (TKI)” PMID 37163774 ↗ Apr 2023 |
| Modality | Small molecule | “tyrosine kinase inhibitor (TKI)” PMID 37163774 ↗ Apr 2023 |
| Route | Oral | “BPI-7711 (180 mg, orally, once daily)” NCT03812809 ↗ |
| Target | EGFR | “epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor” PMID 37163774 ↗ Apr 2023 |